Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters

Journal of Surgical Oncology

Volumn 95, Issue 2, 2007, Pages 123-128

  Saito, Hiroaki ^a   Osaki, Tomohiro ^a   Murakami, Daiki ^a   Sakamoto, Teruhisa ^a   Kanaji, Shingo ^a   Ohro, Shotaro ^a   Tatebe, Shigeru ^a   Tsujitani, Shunichi ^a   Ikeguchi, Masahide ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Dendritic cell; Microvessel; P53; Recurrence; Transforming growth factor 1; Vascular endothelial growth factor

Indexed keywords

PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CELL INFILTRATION; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DENDRITIC CELL; DENSITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PERITONEUM CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DENDRITIC CELLS; FEMALE; GASTRECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STOMACH NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846904316     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20612     Document Type: Article

References (23)

1. Moriguchi S, Maehara Y, Korenaga D, et al.: Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol 1992;1:341-346.
2. Bohner H, Zimmer T, Hopfenmuller W, et al.: Detection and prognosis of recurrent gastric cancer - is routine follow-up after gastrectomy worthwhile? Hepatogastroenterology 2000;47:1489-1494.
3. Saito H, Tsujitani S, Oka S, et al.: The expression of transforming growth factor-beta 1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999;86:1455-1462.
4. Saito H, Tsujitani S, Kondo A, et al.: Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery 1999;125:195-201.
5. Gomyo Y, Ikeda M, Osaki M, et al.: Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997;79:2067-2072.
6. Saito H, Tsujitani S, Ikeguchi M, et al.: Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 1998;78:1573-1577.
7. Japanese Gastric Cancer Association: "Japanese Classification of Gastric Carcinoma." Tokyo: Kanehara, 1999.
8. Koga S, Takebayashi M, Kaibara N, et al.: Pathological characteristics of gastric cancer that develop hematogenous recurrence, with special reference to the site of recurrence. J Surg Oncol 1987;36:239-242.
9. Tsujitani S, Kakeji Y, Watanabe A, et al.: Infiltration of S-100 protein positive dendritic cells and peritoneal recurrence in advanced gastric cancer. Int Surg 1992;77:238-241.
10. Leung DW, Cachianes G, Kuang WJ, et al.: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
11. Maeda K, Chung YS, Ogawa Y, et al.: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-863.
12. Kitadai Y, Haruma K, Tokutomi T, et al.: Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998;4:2195-2200.
13. Gasparini G, Toi M, Gion M, et al.: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-147.
14. Fontanini G, Vignati S, Boldrini L, et al.: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3:861-865.
15. Paley PJ, Staskus KA, Gebhard K, et al.: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80:98-106.
16. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-1093.
17. Finlay CA, Hinds PW, Tan TH, et al.: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-539.
18. Joypaul BV, Hopwood D, Newman EL, et al.: The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994;69:943-946.
19. Zeng ZS, Sarkis AS, Zhang ZF, et al.: p53 nuclear overexpression: An independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 1994;12:2043-2050.
20. Ebina M, Steinberg SM, Mulshine JL, et al.: Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994;54:2496-2503.
21. Kakeji Y, Korenaga D, Tsujitani S, et al.: Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 1993;67:589-593.
22. Sugarbaker PH, Yu W, Yonemura Y: Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: The evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 2003;21:233-248.
23. Sakamoto Y, Ohyama S, Yamamoto J, et al.: Surgical resection of liver metastases of gastric cancer: An analysis of a 17-year experience with 22 patients. Surgery 2003;133:507-511.